{
    "clinical_study": {
        "@rank": "90786", 
        "acronym": "omega3", 
        "arm_group": [
            {
                "arm_group_label": "Test Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks"
            }, 
            {
                "arm_group_label": "Control Group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Omega 3 fatty acids is one such dietary supplement, known to modulate the host response in\n      chronic conditions like cardiovascular diseases, rheumatoid arthritis, ischemic\n      cerebrovascular diseases, osteoporosis by producing Resolvins and protectins without showing\n      any inadvertent effects.Addition of systemic Omega 3 Fatty Acids with SRP may enhance the\n      therapeutic result of Chronic Periodontitis owing to host modulation & anti-inflammatory\n      properties. If proven, this can be used as a routine treatment modality."
        }, 
        "brief_title": "Omega-3 Fatty Acids in Chronic Periodontitis.", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Periodontitis", 
        "condition_browse": {
            "mesh_term": [
                "Periodontitis", 
                "Chronic Periodontitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients within age group of 30 to 55 years.\n\n          2. Systemically healthy individuals.\n\n          3. Patients with chronic generalized periodontitis (moderate and severe)according to\n             Center for Disease Control (CDC) working group, 2007 criteria.\n\n        Exclusion Criteria:\n\n          1. Patients with systemic illnesses (i.e., diabetes mellitus, cancer, human\n             immunodeficiency syndrome, bone metabolic diseases, or disorders that compromise\n             wound healing, radiation, or immunosuppressive therapy),\n\n          2. Smoking,\n\n          3. Chronic alcoholics,\n\n          4. Pregnancy or lactation,\n\n          5. Use of Non Steroidal Anti Inflammatory Drugs, steroids or antibiotics /\n             antimicrobials within September 2012 to August 2013,\n\n          6. Confirmed or suspected intolerance to omega 3 fatty acids,\n\n          7. Periodontal therapy done within the September 2012 to August 2013."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01997853", 
            "org_study_id": "TKDC13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Test Group", 
                "description": "Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks and SRP at baseline", 
                "intervention_name": "Omega 3 fatty acid", 
                "intervention_type": "Drug", 
                "other_name": "Mega-3"
            }, 
            {
                "arm_group_label": "Control Group", 
                "description": "Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks and SRP", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Omega 3 fatty acids", 
            "C Reactive Protein", 
            "Host Modulation", 
            "Chronic Periodontitis"
        ], 
        "lastchanged_date": "November 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kolhapur", 
                    "country": "India", 
                    "state": "Maharashtra", 
                    "zip": "416137"
                }, 
                "name": "Tatyasaheb Kore Dental College and Research Centre, New Pargaon"
            }
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Scaling & Root Planing (SRP) Combined With Therapy Of Omega-3 Fatty Acid on Clinical Parameters and Serum Levels of C-Reactive Protein (CRP) in Chronic Periodontitis - A Randomised Control Trial.", 
        "overall_official": {
            "affiliation": "Post Graduate Student", 
            "last_name": "Girish D Deore, BDS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "India: Indian Council of Medical Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "changes from baseline in biochemical parameter, serum CRP levels were assessed at 6 weeks and 12 weeks after starting therapy with omega 3 fatty acids. Serum CRP level was measured in milligram/liter (mg/l)", 
                "measure": "Change from baseline in serum CRP level at 6 weeks and 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "baseline, 6 weeks, 12 weeks"
            }, 
            {
                "description": "changes from baseline in clinical parameter, PD were assessed at 6 weeks and 12 weeks after starting therapy with omega 3 fatty acids. PD was measured in millimeter.", 
                "measure": "Changes from baseline in pocket depth (PD) at 6 weeks and 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "baseline, 6 weeks and 12 weeks"
            }, 
            {
                "description": "changes from baseline in clinical parameter, CAL were assessed at 6 weeks and 12 weeks after starting therapy with omega 3 fatty acids. CAL was measured in millimeter.", 
                "measure": "Changes from baseline in Clinical Attachment Level (CAL) at 6 weeks and 12 weeks.", 
                "safety_issue": "No", 
                "time_frame": "baseline, 6 weeks and 12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01997853"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tatyasaheb Kore Dental College", 
            "investigator_full_name": "GIRISH DEORE", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "changes from baseline in standard clinical parameter, GI were assessed at 6 weeks and 12 weeks after starting therapy with omega 3 fatty acids. GI has a scoring criteria specified by Silness & Loe, 1963.", 
                "measure": "Changes from baseline in Gingival Index (GI) at 6 weeks and 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "baseline, 6 weeks and 12 weeks"
            }, 
            {
                "description": "changes from baseline in standard clinical parameter, PI were assessed at 6 weeks and 12 weeks after starting therapy with omega 3 fatty acids. PI has a scoring criteria specified by Loe & Silness, 1964.", 
                "measure": "Changes from baseline in Plaque Index (PI) at 6 weeks and 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "baseline, 6 weeks and 12 weeks"
            }, 
            {
                "description": "changes from baseline in standard clinical parameter, OHIS were assessed at 6 weeks and 12 weeks after starting therapy with omega 3 fatty acids. OHIS has a scoring criteria specified by Greene and Vermilion, 1964.", 
                "measure": "Changes from baseline in Oral Hygiene Index Simplified (OHIS) at 6 weeks and 12 weeks.", 
                "safety_issue": "No", 
                "time_frame": "baseline, 6 weeks and 12 weeks"
            }, 
            {
                "description": "changes from baseline in standard clinical parameter, SBI were assessed at 6 weeks and 12 weeks after starting therapy with omega 3 fatty acids. SBI has a scoring criteria specified by Muhleman (1971).", 
                "measure": "Changes from baseline in Sulcus Bleeding Index (SBI) at 6 weeks and 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "baseline, 6 weeks and 12 weeks"
            }
        ], 
        "source": "Tatyasaheb Kore Dental College", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tatyasaheb Kore Dental College", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}